Experimental HCV Drugs
Experimental HCV Drugs
CROI 2012: Studies Look at Interactions Between New Hepatitis C Drugs and HIV Antiretrovirals
- Details
- Category: HCV Treatment
- Published on Thursday, 15 March 2012 00:00
- Written by Liz Highleyman
Drug-drug interactions between direct-acting antiviral agents for hepatitis C and some 
antiretroviral medications used to treat HIV are common, but are often modest and can be managed with dose adjustments when treating people with HIV/HCV coinfection, researchers reported at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) last week in Seattle.
Phase 3 Trials Now Testing HCV Drug TMC435 in Genotype 1 Non-responders and Genotype 4 Patients
- Details
- Category: HCV Treatment
- Published on Tuesday, 13 March 2012 00:00
- Written by Press Release
The next-generation hepatitis C virus (HCV) protease inhibitor TMC435 is now entering 2 new Phase 3 clinical trials, to be used in combination with pegylated interferon/ribavirin for hard-to-treat HCV genotype 1 patients as well as those with genotype 4, according to a company press release.
CROI 2012: GS-7977 Rapidly Suppresses HCV, but Most Patients Relapse after Stopping Treatment
- Details
- Category: HCV Treatment
- Published on Wednesday, 07 March 2012 00:00
- Written by Liz Highleyman
An interferon-free combination of the experimental polymerase inhibitor GS-7977 plus ribavirin potently and rapidly reduced hepatitis C virus (HCV) levels, but almost all patients experienced viral rebound after they stopped treatment, researchers reported Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) this week in Seattle.
CROI 2012: Interactions between HCV Drug Daclatasvir and HIV Antiretrovirals Are Minimal or Manageable
- Details
- Category: HCV Treatment
- Published on Friday, 09 March 2012 00:00
- Written by Liz Highleyman
The investigational hepatitis C virus (HCV) NS5A inhibitor daclatasvir (formerly BMS-790052) showed no clinically relevant effects on blood levels of 3 classes of antiretroviral agents, and changes in daclatasvir levels can likely be overcome by dose adjustment, according to a data presented at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle.
CROI 2012: Telaprevir and Boceprevir Improve Sustained Response Rates in HIV/HCV Coinfected Patients
- Details
- Category: HCV Treatment
- Published on Wednesday, 07 March 2012 00:00
- Written by Liz Highleyman
Adding a first-generation HCV protease inhibitor to pegylated interferon/ribavirin dramatically increases the likelihood of 12-week sustained virological response among HIV/HCV coinfected people, researchers reported Tuesday at the 19th Conference on Retroviruses and Opportunistic Infections (CROI 2012) in Seattle.
More Articles...
- CROI 2012: New Hepatitis C Drugs in Clinical Practice [VIDEO]
- Hepatitis C Advocates Call for Early Studies of Interactions with New HCV Drugs
- Good 12-Week HCV Suppression with Oral Telaprevir/VX-222/Ribavirin Combo
- Hard-to-Treat Hepatitis C Patients Relapse after Stopping Interferon-Free GS-7977/Ribavirin Regimen
Web Design and Development by